Boston Scientific Corporation $BSX Shares Acquired by Vinva Investment Management Ltd

Vinva Investment Management Ltd grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 24.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 68,115 shares of the medical equipment provider’s stock after buying an additional 13,444 shares during the period. Vinva Investment Management Ltd’s holdings in Boston Scientific were worth $7,256,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. Foundations Investment Advisors LLC increased its holdings in Boston Scientific by 8.7% in the 1st quarter. Foundations Investment Advisors LLC now owns 3,599 shares of the medical equipment provider’s stock valued at $363,000 after purchasing an additional 288 shares in the last quarter. N.E.W. Advisory Services LLC purchased a new position in Boston Scientific in the first quarter valued at about $71,000. Vestcor Inc lifted its stake in shares of Boston Scientific by 33.6% during the first quarter. Vestcor Inc now owns 55,637 shares of the medical equipment provider’s stock worth $5,613,000 after purchasing an additional 14,001 shares in the last quarter. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Boston Scientific in the first quarter worth about $1,930,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Leerink Partners boosted their target price on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Robert W. Baird raised their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Finally, Morgan Stanley lifted their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $123.77.

Insider Activity

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 over the last ninety days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

BSX stock opened at $101.14 on Friday. The stock’s 50 day simple moving average is $99.09 and its 200 day simple moving average is $102.28. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The firm has a market cap of $149.93 billion, a P/E ratio of 54.08, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the previous year, the company posted $0.63 earnings per share. The firm’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.